CN102203609B - 用于输血相关急性肺损伤(trali)的筛选方法 - Google Patents

用于输血相关急性肺损伤(trali)的筛选方法 Download PDF

Info

Publication number
CN102203609B
CN102203609B CN200980144058.0A CN200980144058A CN102203609B CN 102203609 B CN102203609 B CN 102203609B CN 200980144058 A CN200980144058 A CN 200980144058A CN 102203609 B CN102203609 B CN 102203609B
Authority
CN
China
Prior art keywords
seq
hna
kit
fragment
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980144058.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102203609A (zh
Inventor
A·格雷纳赫尔
J·韦谢
J·布克斯
A·雷尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Ernst Moritz Arndt
DRK Blutspendedienst West gGmbH
Original Assignee
University Ernst Moritz Arndt
DRK Blutspendedienst West gGmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Ernst Moritz Arndt, DRK Blutspendedienst West gGmbH filed Critical University Ernst Moritz Arndt
Publication of CN102203609A publication Critical patent/CN102203609A/zh
Application granted granted Critical
Publication of CN102203609B publication Critical patent/CN102203609B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200980144058.0A 2008-09-04 2009-09-03 用于输血相关急性肺损伤(trali)的筛选方法 Active CN102203609B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008045696A DE102008045696A1 (de) 2008-09-04 2008-09-04 Granulozyten HNA-3a/b-Antigen
DE102008045696.9 2008-09-04
PCT/EP2009/006386 WO2010025915A1 (en) 2008-09-04 2009-09-03 Screening methods for transfusion related acute lung injury (trali)

Publications (2)

Publication Number Publication Date
CN102203609A CN102203609A (zh) 2011-09-28
CN102203609B true CN102203609B (zh) 2017-07-11

Family

ID=41266687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980144058.0A Active CN102203609B (zh) 2008-09-04 2009-09-03 用于输血相关急性肺损伤(trali)的筛选方法

Country Status (9)

Country Link
US (4) US8084216B2 (enExample)
EP (1) EP2321644B1 (enExample)
JP (1) JP5766606B2 (enExample)
CN (1) CN102203609B (enExample)
AU (2) AU2009289809B2 (enExample)
BR (1) BRPI0918233B8 (enExample)
CA (1) CA2735138C (enExample)
DE (1) DE102008045696A1 (enExample)
WO (1) WO2010025915A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150902A1 (en) 2007-05-29 2008-12-11 Lab Partners Associates, Inc. System and method for maintaining hot shoe communications between a camera and a wireless device
US20090233372A1 (en) * 2008-03-10 2009-09-17 Bonfils Blood Center Compositions, kits and methods for determining etiology of trali and detecting patients at risk for this transfusion reaction
DE102008045696A1 (de) * 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulozyten HNA-3a/b-Antigen
US20110229882A1 (en) * 2008-11-21 2011-09-22 Martin Heath Bluth Diagnosing and monitoring response to treatment of solid organ tissue disease
AU2009322607B2 (en) 2008-12-01 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
AU2014236882B2 (en) 2013-03-14 2019-01-31 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting donor-specific antibodies and systems for practicing the same
US10571468B2 (en) 2014-05-09 2020-02-25 One Lambda, Inc. Modified Fc gamma receptor type III (FCγIII, HNA-1) polypeptides and the uses thereof
US10527613B2 (en) 2015-11-10 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Biomarker detection methods and systems and kits for practicing same
US10640772B2 (en) 2015-11-30 2020-05-05 Nissan Chemical Industries, Ltd. DNA aptamers binding to molecular targeted agents and detection method of molecular targeted medicine using the same
AU2016402264B2 (en) * 2016-04-15 2024-08-22 Pontificia Universidad Católica De Chile Pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and the use thereof
CN116536401A (zh) * 2022-01-26 2023-08-04 上海市血液中心 一种基于质谱的血小板和中性粒细胞抗原、糖蛋白的基因分型方法和试剂盒
CN116083551B (zh) * 2022-10-11 2025-02-21 南宁中心血站(南宁输血医学研究所) 用于检测人类中性粒细胞抗原基因分型的引物组合、试剂盒及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219777A1 (en) * 2001-12-18 2003-11-27 Lynx Therapeutics, Inc. Identification of candidate genes for the atherosclerosis susceptibility locus (ATHS)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411051B2 (en) * 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20030082646A1 (en) 1998-12-29 2003-05-01 The Regents Of The University Of Michigan Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL
JP2004507202A (ja) 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
FR2800750B1 (fr) * 1999-11-05 2003-01-31 Centre Nat Rech Scient Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
DE10028725B4 (de) 2000-06-09 2013-03-21 Jürgen Bux Primärstruktur des HNA-2a (ehemals NB1)-Antigens
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7829292B2 (en) * 2002-05-06 2010-11-09 The Regents Of The University Of Michigan Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
EP2196474A3 (en) * 2003-02-14 2010-12-15 Sagres Discovery, Inc. Therapeutic targets in cancer
US7303985B2 (en) * 2003-11-17 2007-12-04 Intel Corporation Zeolite-carbon doped oxide composite low k dielectric
KR20080108563A (ko) * 2006-03-23 2008-12-15 니혼 세키쥬지샤 과립구 항체 검출용 패널세포
DE102008045696A1 (de) 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulozyten HNA-3a/b-Antigen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219777A1 (en) * 2001-12-18 2003-11-27 Lynx Therapeutics, Inc. Identification of candidate genes for the atherosclerosis susceptibility locus (ATHS)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
An electric lobe suppressor for a yeast choline transport mutation belongs to a new family of transporter-like proteins;O’REGAN,S.et al;《PNAS》;20000215;第97卷(第4期);1835-1840 *
ORIGINAL PAPER Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors;A. Reil et al;《Vox Sanguinis》;20080812;第95卷(第4期);313-317 *
TRALI due to granulocyte-arrlutinating human neutrophil antigen-3a(5b) alloantibodies in donor plasma:a report of 2 fatalities;Bethesda;《American Association of Blood Banks》;20030501;第43卷(第5期);641-645 *

Also Published As

Publication number Publication date
BRPI0918233A2 (pt) 2015-12-15
BRPI0918233B8 (pt) 2021-07-27
BRPI0918233B1 (pt) 2020-12-01
US20100055706A1 (en) 2010-03-04
AU2009289809B2 (en) 2016-07-07
JP5766606B2 (ja) 2015-08-19
US8084216B2 (en) 2011-12-27
JP2012501631A (ja) 2012-01-26
US20120070834A1 (en) 2012-03-22
AU2009289809A1 (en) 2010-03-11
US20130189696A1 (en) 2013-07-25
EP2321644A1 (en) 2011-05-18
CN102203609A (zh) 2011-09-28
US9963741B2 (en) 2018-05-08
US20150203915A1 (en) 2015-07-23
AU2016204135A1 (en) 2016-07-14
CA2735138C (en) 2021-06-01
EP2321644B1 (en) 2016-12-14
US8435733B2 (en) 2013-05-07
CA2735138A1 (en) 2010-03-11
AU2009289809A8 (en) 2011-05-12
WO2010025915A1 (en) 2010-03-11
DE102008045696A1 (de) 2010-03-11
US8999651B2 (en) 2015-04-07

Similar Documents

Publication Publication Date Title
JP5766606B2 (ja) 輸血関連急性肺障害（ｔｒａｌｉ）に関するスクリーニング方法
US8628932B2 (en) Methods of detecting antibodies specific for denatured HLA antigens
US7972804B2 (en) Methods of detecting antibodies specific for denatured HLA antigens
CA2814023C (en) Moesin fragments and uses thereof
JP2024056941A (ja) 抗第ＩＸ因子Ｐａｄｕａ抗体
CA2814026C (en) Moesin fragments associated with aplastic anemia
CA2814029C (en) Moesin fragments associated with immune thrombocytopenia
US20100104581A1 (en) Methods for Diagnosing and Treating Graft Rejection and Inflammatory Conditions
WO2010096160A1 (en) Compartment-specific non-hla targets for diagnosis and prediction of graft outcome
JP2008523398A (ja) インスリン抵抗性の標的／マーカーとしてのｃｄ９９
WO2022007283A1 (zh) 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质
Wallace et al. Practical Atlas of Transplant Pathology
JP2009013175A (ja) 抗ｈｐａ
JP2009013175A6 (ja) 抗ｈｐａ
JP5876673B2 (ja) 精神障害の診断方法および診断薬キット
JP6721571B2 (ja) １５種類の男性生殖関連タンパク質またはその組み合わせの使用
JP4838436B2 (ja) 抗ヒト肝性トリグリセリドリパーゼ抗体
US20250216401A1 (en) Method of detecting human leukocyte antigens (hla)
JP2007282553A (ja) 動脈硬化感受性遺伝子およびその用途
JPWO2004094638A1 (ja) 血管炎抗原ペプチドと血管炎診断方法
WO2004048412A2 (en) Method for the generation of antibodies against a desired antigen using preselected animals for immunization

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant